Patents by Inventor James R. Rusche

James R. Rusche has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • HISTONE DEACETYLASE INHIBITORS
    Publication number: 20170044186
    Abstract: This invention relates to generally inhibiting histone deacetylase (“HDAC”) enzymes (e.g., HDAC1, HDAC2, and HDAC3).
    Type: Application
    Filed: October 28, 2016
    Publication date: February 16, 2017
    Inventors: Vincent Jacques, James R. Rusche, Norton P. Peet, Jasbir Singh
  • Histone deacetylase inhibitors
    Patent number: 9540395
    Abstract: This invention relates to generally inhibiting histone deacetylase (HDAC) enzymes (e.g., HDAC1, HDAC2, and HDAC3).
    Type: Grant
    Filed: February 28, 2012
    Date of Patent: January 10, 2017
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Vincent Jacques, James R. Rusche, Norton P. Peet, Jasbir Singh
  • Histone deacetylase inhibitors
    Patent number: 9512143
    Abstract: The compounds provided herein are phenyl analine amides and are useful for inhibiting histone deacteylase (“HDAC”) enzymes, such as HDAC1, HDAC2, and HDAC3.
    Type: Grant
    Filed: January 16, 2015
    Date of Patent: December 6, 2016
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventors: Vincent Jacques, James R. Rusche, Norton P. Peet, Jasbir Singh
  • COMPOSITIONS INCLUDING 6-AMINOHEXANOIC ACID DERIVATIVES AS HDAC INHIBITORS
    Publication number: 20160122290
    Abstract: This invention relates to compounds of Formula (I) wherein Cy1, L1, Y, R1, L2, and Ar2 are defined herein, for the treatment of cancers, inflammatory disorders, and neurological conditions.
    Type: Application
    Filed: January 12, 2016
    Publication date: May 5, 2016
    Inventors: James R. Rusche, Norton P. Peet, Allen Hopper
  • Compositions including 6-aminohexanoic acid derivatives as HDAC inhibitors
    Patent number: 9265734
    Abstract: This invention relates to compounds of Formula (I) wherein Cy1, L1, Y, R1, L2, and Ar2 are defined herein, for the treatment of cancers, inflammatory disorders, and neurological conditions.
    Type: Grant
    Filed: September 3, 2009
    Date of Patent: February 23, 2016
    Assignee: BIOMARIN PHARMACEUTICAL INC.
    Inventors: James R. Rusche, Norton P. Peet, Allen T. Hopper
  • HDAC INHIBITORS
    Publication number: 20160031823
    Abstract: Disclosed herein are compounds of formula (I), and methods of inhibiting histone deacetylase (“HDAC”) enzymes (e.g., HDAC1, HDAC2, and HDAC3) using compounds of formula (I).
    Type: Application
    Filed: March 14, 2014
    Publication date: February 4, 2016
    Inventors: Vincent Jacques, James R. Rusche
  • HISTONE DEACETYLASE INHIBITORS
    Publication number: 20150158884
    Abstract: This invention relates to generally inhibiting histone deacetylase (“HDAC”) enzymes (e.g., HDAC1, HDAC2, and HDAC3).
    Type: Application
    Filed: January 16, 2015
    Publication date: June 11, 2015
    Inventors: Vincent Jacques, James R. Rusche, Norton P. Peet, Jasbir Singh
  • Histone deacetylase inhibitors
    Patent number: 8957066
    Abstract: This invention relates to generally inhibiting histone deacetylase (“HDAC”) enzymes (e.g., HDAC1, HDAC2, and HDAC3) using compounds of formula (I), wherein the substituents are as defined herein.
    Type: Grant
    Filed: March 15, 2013
    Date of Patent: February 17, 2015
    Assignee: Biomarin Pharmaceutical Inc.
    Inventors: Vincent Jacques, James R Rusche, Norton P. Peet, Jasbir Singh
  • Histone Deacetylase Inhibitors
    Publication number: 20140051680
    Abstract: This invention relates to generally inhibiting histone deacetylase (HDAC) enzymes (e.g., HDAC1, HDAC2, and HDAC3).
    Type: Application
    Filed: February 28, 2012
    Publication date: February 20, 2014
    Applicant: REPLIGEN CORPORATION
    Inventors: Vincent Jacques, James R. Rusche, Norton P. Peet, Jasbir Singh
  • Compositions Including 6-Aminohexanoic Acid Derivatives As HDAC Inhibitors
    Publication number: 20120094971
    Abstract: This invention relates to compounds of Formula (I) wherein Cy1, L1, Y, R1, L2, and Ar2 are defined herein, for the treatment of cancers, inflammatory disorders, and neurological conditions.
    Type: Application
    Filed: September 3, 2009
    Publication date: April 19, 2012
    Applicant: REPLIGEN CORPORATION
    Inventors: James R. Rusche, Norton P. Peet, Allen T. Hopper
  • METHODS OF IDENTIFYING HISTONE DEACETYLASE INHIBITORS USEFUL FOR NEUROLOGICAL DISORDERS
    Publication number: 20100285476
    Abstract: A method of identifying a candidate compound for treatment of a neurological condition includes obtaining a test compound; assaying a first activity of the test compound to inhibit histone deacetylase activity of a histone deacetylase 3 (HDAC3); assaying a second activity of the test compound to inhibit histone deacetylase activity of a histone deacetylase other than a HDAC3; and identifying the test compound as a candidate compound for treatment of a neurological condition if the first activity of the test compound is greater than the second activity of the test compound.
    Type: Application
    Filed: October 24, 2008
    Publication date: November 11, 2010
    Inventors: James R. Rusche, Andrew Cooper
  • Methylxanthines in the diagnosis and treatment of autistic disorder
    Patent number: 6365593
    Abstract: The invention is based on the discovery that the levels of one or more methylxanthines in urine samples are significantly decreased in children diagnosed with symptoms of autistic disorder, compared to the levels in normal children, and that levels of xanthines in urine are increased in autistic children. Consequently, the presence in the urine of levels of methylxanthines below a certain range and the level of xanthine above a certain range, are diagnostic of autistic disorder. In another aspect, one or more of these methylxanthines can be used to treat individuals exhibiting symptoms of autistic disorder.
    Type: Grant
    Filed: April 12, 2001
    Date of Patent: April 2, 2002
    Assignee: Repligen Corporation
    Inventors: James R. Rusche, Jundong Zhang
  • Methylxanthines in the diagnosis and treatment of autistic disorder
    Publication number: 20020019407
    Abstract: The invention is based on the discovery that the levels of one or more methylxanthines in urine samples are significantly decreased in children diagnosed with symptoms of autistic disorder, compared to the levels in normal children, and that levels of xanthines in urine are increased in autistic children. Consequently, the presence in the urine of levels of methylxanthines below a certain range and the level of xanthine above a certain range, are diagnostic of autistic disorder. In another aspect, one or more of these methylxanthines can be used to treat individuals exhibiting symptoms of autistic disorder.
    Type: Application
    Filed: April 12, 2001
    Publication date: February 14, 2002
    Inventors: James R. Rusche, Jundong Zhang
  • Method for detecting inhibitors of tat protein
    Patent number: 5278042
    Abstract: A method for evaluating the inhibitory effect of a substance on tat-protein TAR RNA binding is described. A test system for determining the association of tat-protein with TAR RNA is also included within the scope of the invention.
    Type: Grant
    Filed: February 6, 1989
    Date of Patent: January 11, 1994
    Assignee: The United States of America as represented by the Department of Health & Human Services
    Inventors: Flossie Wong-Staal, Jay Rappaport, James R. Rusche
  • Thioredoxin shufflease and use thereof
    Patent number: 4904602
    Abstract: The subject invention concerns a novel enzyme named thioredoxin shufflease, means for preparing the same, and procedures for using thioredoxin shufflease to fold proteins containing disulfide crosslinks. Thioredoxin shufflease is a generic term to define enzymes which have the following characteristics: (a) contain a single reactive thiol group; (b) catalyze the exchange of disulfides in a protein undergoing the refolding process; and (c) are not consumed in the oxidation/refolding process. Specifically exemplified is a thioredoxin shufflease produced from an E. coli thioredoxin gene.
    Type: Grant
    Filed: August 8, 1986
    Date of Patent: February 27, 1990
    Assignee: Repligen Corporation
    Inventors: Vincent P. Pigiet, James R. Rusche, Barbara J. Schuster